GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gaush Meditech Ltd (HKSE:02407) » Definitions » Cash Flow from Financing

Gaush Meditech (HKSE:02407) Cash Flow from Financing : HK$98.7 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Gaush Meditech Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, Gaush Meditech paid HK$0.0 Mil more to buy back shares than it received from issuing new shares. It received HK$0.0 Mil from issuing more debt. It paid HK$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received HK$0.0 Mil from paying cash dividends to shareholders. It received HK$0.0 Mil on other financial activities. In all, Gaush Meditech spent HK$0.0 Mil on financial activities for the six months ended in Dec. 2023.


Gaush Meditech Cash Flow from Financing Historical Data

The historical data trend for Gaush Meditech's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gaush Meditech Cash Flow from Financing Chart

Gaush Meditech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
-83.98 1,015.15 89.19 3.44 -207.75

Gaush Meditech Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial -7.16 -99.97 98.67 - -

Gaush Meditech Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Gaush Meditech's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Gaush Meditech's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$98.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gaush Meditech  (HKSE:02407) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Gaush Meditech's issuance of stock for the six months ended in Dec. 2023 was HK$0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Gaush Meditech's repurchase of stock for the six months ended in Dec. 2023 was HK$0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Gaush Meditech's net issuance of debt for the six months ended in Dec. 2023 was HK$0.0 Mil. Gaush Meditech received HK$0.0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Gaush Meditech's net issuance of preferred for the six months ended in Dec. 2023 was HK$0.0 Mil. Gaush Meditech paid HK$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Gaush Meditech's cash flow for dividends for the six months ended in Dec. 2023 was HK$0.0 Mil. Gaush Meditech received HK$0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Gaush Meditech's other financing for the six months ended in Dec. 2023 was HK$0.0 Mil. Gaush Meditech received HK$0.0 Mil on other financial activities.


Gaush Meditech Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Gaush Meditech's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Gaush Meditech (HKSE:02407) Business Description

Traded in Other Exchanges
Address
No.11 Dongzhimen South Avenue, Room 1901, Building A, Zhonghui Plaza, Dongcheng District, Beijing, CHN
Gaush Meditech Ltd is a provider of a broad spectrum of ophthalmic medical devices. The segments of the company include 1) Proprietary products segment develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; 2) Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; 3) Technical services segment provides warranty services, maintenance services and after-sales services related consumables; and 4) Others segment.
Executives
Orbimed Advisors Iii Limited 2102 Investment manager
Orbimed Asia Gp Iii, L.p. 2102 Investment manager
Orbimed Asia Partners Iii, L.p. 2102 Investment manager
Gao Tieta 2201 Interest of corporation controlled by you
Gaush Holding Ltd 2101 Beneficial owner
Cuprite Gem Investments Ltd 2101 Beneficial owner
Warburg Pincus (bermuda) Private Equity Gp Ltd. 2201 Interest of corporation controlled by you
Warburg Pincus (cayman) China-southeast Asia Ii Gp Llc 2201 Interest of corporation controlled by you
Warburg Pincus (cayman) China-southeast Asia Ii Gp, L.p. 2201 Interest of corporation controlled by you
Warburg Pincus China-southeast Asia Ii (cayman), L.p. 2201 Interest of corporation controlled by you
Warburg Pincus Partners Ii (cayman), L.p. 2201 Interest of corporation controlled by you

Gaush Meditech (HKSE:02407) Headlines

No Headlines